Progestogens share one common effect: the ability to convert proliferative endometrium to its secretory
form. In contrast, their biological activity is varied, depending on the chemical structure, pharmacokinetics,
receptor affinity and different potency of action. Progestogens are widely used in the treatment of menstrual cycle disturbances, various gynaecological conditions, contraception and menopausal hormone therapy.
The administration of progestogen in menopausal hormone therapy is essential in women with an intact uterus
to protect against endometrial hyperplasia and cancer. Progestogen selection should be based on the characteristics available for each progestogen type, relying on the assessment of relative potency of action in experimental models and animal models, and on the indirect knowledge brought by studies of the clinical use of different progestogen formulations. The choice of progestogen should involve the conscious use of knowledge of
its benefits, with a focus on minimizing potential side effects. Unfortunately, there are no direct clinical studies
comparing the metabolic effects of different progestogens.
pl
dc.subject.en
progestogens
pl
dc.subject.en
menopausal hormone
pl
dc.subject.en
therapy
pl
dc.subject.en
progesterone
pl
dc.subject.en
progestin
pl
dc.description.volume
14
pl
dc.description.number
2
pl
dc.description.points
8
pl
dc.identifier.doi
10.5114/pm.2015.52154
pl
dc.identifier.eissn
2299-0038
pl
dc.title.journal
Przegląd Menopauzalny
pl
dc.language.container
pol
pl
dc.affiliation
Wydział Lekarski : Zakład Farmakologii Klinicznej
pl
dc.subtype
ReviewArticle
pl
dc.rights.original
CC-BY-NC-SA; otwarte czasopismo; ostateczna wersja wydawcy; w momencie opublikowania; 0
Except where otherwise noted, this item's license is described as Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Na tych samych warunkach 4.0 Międzynarodowa